ADMA Biologics/$ADMA

13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX

About ADMA Biologics

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

Ticker

$ADMA
Primary listing

Industry

Biotechnology

Employees

685

ISIN

US0008991046

ADMA Biologics Metrics

BasicAdvanced
$4.4B
22.02
$0.84
0.57
-

What the Analysts think about ADMA Biologics

Analyst ratings (Buy, Hold, Sell) for ADMA Biologics stock.

Bulls say / Bears say

ADMA Biologics received FDA approval for its plasma yield enhancement process, expected to increase production yields by approximately 20%, potentially boosting revenue and earnings starting in late 2025. (reuters.com)
The company reported a 59.1% year-over-year revenue increase to $117.55 million in Q4 2024, indicating strong financial growth. (reuters.com)
Analysts maintain a 'buy' rating on ADMA Biologics, with a median 12-month price target of $25.00, suggesting confidence in the company's future performance. (reuters.com)
The unexpected resignation of ADMA Biologics' independent auditor, CohnReznick LLP, in October 2024 led to a significant stock price decline and raised concerns about financial oversight. (bloomberglaw.com)
Following the auditor's resignation, multiple law firms initiated investigations into potential securities fraud, which could result in legal challenges and financial penalties. (globenewswire.com)
Despite strong revenue growth, ADMA Biologics' Q4 2024 adjusted earnings per share of $0.14 missed analyst expectations of $0.15, indicating potential challenges in meeting profitability targets. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.

ADMA Biologics Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ADMA Biologics Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ADMA

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs